鶹ֱ
鶹ֱ & Lardner LLP partner Thomas Ferrante was quoted on growing regulatory and patient safety concerns in the Digital Health Insights article, “.”
Ferrante discussed the increased focus on oversight and compliance in the industry, citing the FDA’s March 2026 warning letters to companies over marketing of GLP-1s. He added though that, “No one’s getting shut down from just those warning letters to start. They give the industry a chance to change, to comply.”
On certain telemedicine platforms receiving criticism for operating asynchronous models and not providing required clinical support after prescribing GLP-1s, Ferrante said, “Some of those online platforms, I think, are a little aggressive. There’s almost no clinical interaction. There’s no follow up.”
“Things can be done asynchronously, but it doesn’t mean you abandon that clinical standard of care,” he added.
